Clinician perspective on achieving and maintaining remission in depression

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 26, 2001, Pages 16-21

  Kelsey, J E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; ESTROGEN; FOLIC ACID; IMIPRAMINE; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PINDOLOL; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RECURRENT DISEASE; RELAPSE; REMISSION; WELLBEING;

ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; PSYCHOTHERAPY; REMISSION INDUCTION;

EID: 0035661658     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. Prevalence of anxiety, depression and substance use disorders in an urban general medicine practice
2. Common mental disorders and disability across cultures: Results from the WHO Collaborative Study on Psychological Problems in General Health Care
3. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment
4. The quality of care for depressive and anxiety disorders in the United States
5. Residual symptoms after partial remission: An important outcome in depression
6. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders
7. Depression in medical outpatients: Underrecognition and misdiagnosis
8. Collaborative management to achieve treatment guidelines: Impact on depression in primary care
9. Recognition, management, and outcomes of depression in primary care
10. Recovery from major depression: A 10-year prospective follow-up across multiple episodes
11. Relapse of depression in primary care: Rate and clinical predictors
12. Remission and relapse in major depression: A two-year prospective follow-up study
13. Management of general medical patients with symptoms of depression
14. Patterns of antidepressant use in community practice
15. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression
16. Time to recovery, chronicity, and levels of psychopathology in major depression: A 5-year prospective follow-up of 431 subjects
17. Treatment of major depression: Is improvement enough?
18. Clinical guidelines for establishing remission in patients with depression and anxiety
19. Evolution of remission as the new standard in the treatment of depression
20. Remission as the goal of treatment of depression: A Qualitative review of comparative studies
21. Mood disorders, 1: Major depressive disorders
22. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression
23. Citalopram: Clinical effect profile in comparison with clomipramine: A controlled multicenter study
24. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
25. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder
26. Mechanism of action of antidepressant medications
27. SNaRls, NaSSAs, and NaRls: New agents for the treatment of depression
28. Mirtazapine: A review of its use in major depression
29. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: A comparative study with paroxetine and desipramine
30. A randomized, placebocontrolled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression
31. Four-year outcome for cognitive behavioral treatment of residual symptoms in major depression
32. Psychotherapeutic approaches to the treatment of anxiety and depressive disorders
33. Prevention of recurrent depression with cognitive behavioral therapy: Preliminary findings
34. Depression in the medical setting: Biopsychological interactions and treatment considerations
35. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: Initial findings
36. Effects of trazodone and fluoxetine in the treatment of major depression: Therapeutic pharmacokinetic and pharmacodynamic interactions through formation of metachlorophenylpiperazine
37. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSR1 in patients with treatment-refractory depression
38. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression
39. A novel augmentation strategy for treating resistant major depression
40. Comparison of 2 treatment strategies for depressed inpatients: Imipramine and lithium addition or mirtazapine and lithium addition
41. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: A double-blind study
42. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapyresistant depressive patients: A clinical, pharmacokinetic, and pharmacogenetic investigation
43. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial
44. Preliminary randomized doubleblind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: Antidepressant and hypnotic effects
45. Pindolol augmentation of antidepressants: A review and rationale
46. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial
47. The pharmacology of antidepressants at the synapse: Focus on newer compounds
48. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression
49. Treatment of depression
50. Reboxetine plus citalopram in treatmentresistant depression
51. Pharmacodynamic and pharmacokinetic interactions of selective serotonin re-uptake inhibiting antidepressants (SSRIs) with other psychotropic drugs
52. Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs
53. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor
54. Trazodone, nefazodone, bupropion, and mirtazapine
55. The pharmacology and mode of action of venlafaxine
56. The use of complementary and alternative therapies to treat anxiety and depression in the United States
57. Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: Are they related?
58. Fast-onset antidepressants
59. Strategies and tactics in the treatment of chronic depression
60. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates
61. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
62. Venlafaxine XR is superior to placebo in relapse prevention for patients with major depressive disorder
63. Venlafaxine in the preventive treatment of recurrent major depressive disorder